Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
23 September 2021Website:
http://www.xortx.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 22:00:28 GMTDividend
Analysts recommendations
Institutional Ownership
XRTX Latest News
CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company specializing in treatments for progressive kidney disease, has received approval from the TSX Venture Exchange to adjust the terms of outstanding common share purchase warrants issued on October 15, 2021. The original exercise price of the warrants, which were previously repriced in connection with a private placement on October 7, 2022, has been amended to USD $5.00 on a post-consolidation basis for 910,000 warrants (101,111 post 9:1 consolidation).
Xortx Therapeutics (NASDAQ: XRTX ) stock is sliding lower on Monday as the pharmaceutical company's shares come off of a recent rally. Shares of XRTX stock closed out normal trading hours on Friday up 100.6%.
Xortx Therapeutics (NASDAQ: XRTX ) stock is climbing higher on Friday despite a lack of news from the pharmaceutical company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) from Xortx Therapeutics that would cause today's rally.
What type of business is XORTX Therapeutics?
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
What sector is XORTX Therapeutics in?
XORTX Therapeutics is in the Healthcare sector
What industry is XORTX Therapeutics in?
XORTX Therapeutics is in the Biotechnology industry
What country is XORTX Therapeutics from?
XORTX Therapeutics is headquartered in Canada
When did XORTX Therapeutics go public?
XORTX Therapeutics initial public offering (IPO) was on 23 September 2021
What is XORTX Therapeutics website?
https://www.xortx.com
Is XORTX Therapeutics in the S&P 500?
No, XORTX Therapeutics is not included in the S&P 500 index
Is XORTX Therapeutics in the NASDAQ 100?
No, XORTX Therapeutics is not included in the NASDAQ 100 index
Is XORTX Therapeutics in the Dow Jones?
No, XORTX Therapeutics is not included in the Dow Jones index
When does XORTX Therapeutics report earnings?
Next earnings report date is not announced yet